Open AccessThe Epstein–Barr virus LMP1 interactome: biological implications and therapeutic targets
Author(s) -
Mujeeb R. Cheerathodi,
David G. Meckes
Publication year - 2018
Publication title -
future virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.462
H-Index - 34
eISSN - 1746-0808
pISSN - 1746-0794
DOI - 10.2217/fvl-2018-0120
Subject(s) - interactome , signal transduction , biology , epstein–barr virus , virus , cancer research , computational biology , microbiology and biotechnology , virology , genetics , gene
The oncogenic potential of Epstein-Barr virus (EBV) is mostly attributed to latent membrane protein 1 (LMP1), which is essential and sufficient for transformation of fibroblast and primary lymphocytes. LMP1 expression results in the activation of multiple signaling cascades like NF-ΚB and MAP kinases that trigger cell survival and proliferative pathways. LMP1 specific signaling events are mediated through the recruitment of a number of interacting proteins to various signaling domains. Based on these properties, LMP1 is an attractive target to develop effective therapeutics to treat EBV-related malignancies. In this review, we focus on LMP1 interacting proteins, associated signaling events, and potential targets that could be exploited for therapeutic strategies.